41 results about "Taurocholic acid" patented technology

Provided are novel benzothiepines, derivatives, and analogs thereof; pharmaceutical compositions containing them; and methods of using these compounds and compositions in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals.

Provided are novel benzothiepines, derivatives, and analogs thereof; pharmaceutical compositions containing them; and methods of using these compounds and compositions in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals.

Thiepine apical sodium co-dependent bile acid transport (ASBT) inhibitors are disclosed together with methods of making the same, methods of using the same to treat hyperlipidemic conditions as well as pharmaceutical compositions containing the same compounds.

The invention relates to the technical field of medical diagnostics, in particular to a small molecule metabolite map for identifying liver cancer, hepatitis or liver cirrhosis and a manufacturing method thereof. The small molecule metabolites are four blood metabolites markers, i.e. palmitoyl hemolysis phosphoric acid ethanolamine glyceride, docosapentaenoic acyl hemolysis phosphatidyl choline, docosahexaenoic acyl hemolysis phosphatidyl choline and taurocholic acid, which respectively have the molecular weight of 453.2855, 569.3481, 567.3319 and 516.2916, and the corresponding ions of 454.2928, 570.3547, 568.3391 and 480.2776 detected through mass spectrum. Through experimentation on animals, the accuracy for determination of the liver cancer phase of a rat is 85 percent, and the accuracy for determination of the hepatitis or the liver cirrhosis is 94 percent. Clinical experiment results show that the accuracy for determination of the liver cancer is 85 percent, and the accuracy for determination of non-liver cancer is 71.9 percent. The method provided by the invention has the advantages of high sensitivity and high throughput, is superior to the existing liver cancer single diagnosis marker, and is applicable to screening and assisted diagnosis of the liver cancer.

Thiepine apical sodium co-dependent bile acid transport (ASBT) inhibitors are disclosed together with methods of making the same, methods of using the same to treat hyperlipidemic conditions as well as pharmaceutical compositions containing the same compounds.

Provided are novel benzothiepines, derivatives, and analogs thereof; pharmaceutical compositions containing them; and methods of using these compounds and compositions in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals.

A method of treating a patient to reduce risk of developing Clostridium difficile-associated disease or reducing existing Clostridium difficile-associated disease in a mammalian subject involves administering to a mammalian subject an effective amount of a germination-inhibiting compound derived from taurocholate. Novel compounds of this class are also provided.

The invention discloses 7 alpha-hydroxysteroid dehydrogenase as well as a coding gene and application thereof. An amino acid sequence of the 7 alpha-hydroxysteroid dehydrogenase provided by the invention is shown as SEQ ID NO. 1, and a nucleotide sequence of the 7 alpha-hydroxysteroid dehydrogenase gene is disclosed and shown as SEQ ID NO. 2. The 7 alpha-hydroxysteroid dehydrogenase can catalyze asubstrate taurocholic acid (TCA) to generate taurine 7-ketone cholic acid (T7K-CA), catalyze a substrate glycocholic acid (GCA) to generate glycine 7-ketone cholic acid (G7K-CA), catalyze a substratetaurochenodeoxycholic acid (TCDCA) to generate taurine 7-ketone lithocholic acid (T7K-LCA), catalyze a substrate glycochenodeoxycholic acid (GCDCA) to generate glycine 7-ketone lithocholic acid (G7K-LCA) and catalyze a substrate ethyl benzoylformate (EB) to generate ethyl 2-hydroxy-2-phenylacetate, and has better catalytic activity, has a catalytic activity to TCDCA, GCDCA and EB 10, 5, and 3 times that of sardinia clostridium 7 alpha-HSDH, correspondingly, and has great industrial application value.

The invention discloses a kit. The kit comprises a reagent R1 and a reagent R2, the reagent R1 contains a trihydroxymethyl aminomethane (Tris-HCL) buffer solution, an anti-taurine antibody, an anti-glycocholic acid antibody and glucose-6-phosphate (G6P), and the reagent R2 contains the trihydroxymethyl aminomethane (Tris-HCL) buffer solution, a glycocholic acid-G-6-PD conjugate, NADP and BSA. The invention further discloses a preparation method of the kit, particularly discloses a preparation method of the anti-taurine antibody the anti-glycocholic acid antibody and further discloses a method for detecting peripheral blood glycocholic acid through the kit. Accordingly, interference of taurocholic acid can be avoided, the detection sensitivity reaches up to 0.1 microgram per milliliter, and the advantages of high specificity and detection repeatability, good stability and the like are achieved.

The invention discloses a kit. The kit comprises a reagent R1 and a reagent R2, the reagent R1 contains a trihydroxymethyl aminomethane (Tris-HCL) buffer solution, an anti-taurine antibody, an anti-glycocholic acid antibody and glucose-6-phosphate (G6P), and the reagent R2 contains the trihydroxymethyl aminomethane (Tris-HCL) buffer solution, a glycocholic acid-G-6-PD conjugate, NADP and BSA. The invention further discloses a preparation method of the kit, particularly discloses a preparation method of the anti-taurine antibody the anti-glycocholic acid antibody and further discloses a method for detecting peripheral blood glycocholic acid through the kit. Accordingly, interference of taurocholic acid can be avoided, the detection sensitivity reaches up to 0.1 microgram per milliliter, and the advantages of high specificity and detection repeatability, good stability and the like are achieved.

The invention discloses a method for extracting taurocholic acid in sheep bile through a column chromatography isolation method. The method comprises the following steps: filtering, performing protein precipitation treatment, performing depigmentation treatment, salting out, extracting, dewatering concentration and performing column chromatography isolation. According to the method, the sheep bile serves as an extracting raw material, the extraction cost of the taurocholic acid is reduced, the extraction process is simple, and the income is higher. The taurocholic acid is extracted through the column chromatography isolation, the column chromatography isolation is good in purification effect, the extracted taurocholic acid does not have a fishy smell and is high in purity, the product is high in yield, the extraction process is simple, and industrial production is promoted.

The invention provides a medicinal simulation calculus bovis; compared with the existing other artificial calculus bovis, the medicinal simulation calculus bovis is characterized in that the medicinal simulation calculus bovis uses calcium bilirubinate as main component, a relatively large amount of conjugated bile acid (glycocholic acid, taurocholic acid, and the like) is added, proteins (comprising mucoprotein, polypeptide, and the like) and lecithin are used as component substances, the hyodeoxycholic acid in the traditional formula of artificial calculus bovis is removed so as to reduce the ratio of free cholesteric acid, the technology of preparing calcium bilirubinate with a bacterial fermentation method is eliminated and starch is removed as accessory, and the compound ratio and existing manner in the formula is almost completely the same as natural calculus bovis. The medicinal simulation calculus bovis has better drug effect than the existing other artificial calculus bovis.

The present invention provides pharmaceutical compositions comprising the chemotherapy drug gemcitabine (GEM) and certain derivatives, a taurocholic acid (TCA) formulation, and a Histidine-Lysine Polymer (HKP) conjugate, for enhancement of RNAi cancer therapeutics.

The invention belongs to the technical field of pharmaceutical preparation and particularly relates to an oral curcumin nano-granule and a preparation method thereof. The nano-granule is prepared by self-assembling a ternary conjugated compound which is obtained by connecting taurocholic acid, heparin and curcumin through amido bonds, the curcumin is a core of the nano-granule, and the hydrophilic taurocholic acid is on the surface of the nano-granule. The oral curcumin nano-granule overcomes the poor water solubility of curcumin, the absorption of the nano-granule can be enhanced by utilizing the interaction of taurocholic acid and bile acid transporter of small intestine, the defect that the bioavailability of the oral curcumin is low can be overcome, and the heparin also has anti-thrombosis and anti-angiogenesis effect.

The invention relates to a traditional Chinese medicinal composition, and concretely relates to an antitumor traditional Chinese medicinal composition and an antitumor active component composition, and a use and a preparation thereof. The antitumor traditional Chinese medicinal composition comprises, by weight, 30-60 parts of Panax Notoginseng, 5-15 parts of artificial bezoar, 1-8 parts of artificial musk and 1-10 parts of snake galls. The antitumor active component composition comprises, by weight, 10-30 parts of Panax notoginseng saponins, 1-8 parts of cholic acid, 0.1-1 part of musk ketoneand 0.1-1 part of taurocholic acid. The traditional Chinese medicinal composition or the active component composition has the advantages of low price, clear components, clear mechanism, accurate dosage, safety and effectiveness, and is used for preventing or treating various malignant tumors.

The invention provides a composition applied on a navel for preventing and treating obesity, belonging to the technical field of obesity treatment. The composition is prepared from cattle bitter gallpowder, pig bitter gall powder, radix et rhizoma rhei and ginger juice; the weight ratio of the cattle bitter gall powder to the pig bitter gall powder to the radix et rhizoma rhei is (10-20) to (10-20) to (1-2), the ratio of the mass of the cattle bitter gall powder to the volume of the ginger juice is (10-20)g to (2-5)ml; the cattle bitter gall powder is prepared from taurocholic acid, calculusbovis deoxycholic acid, glycocholic acid and glycodeoxycholic acid hydrate; the pig bitter gall powder is prepared from hyocholic acid and hyodeoxycholic acid. The composition for preventing and treating obesity can be used for reducing weight, and any side effects are not seen.

The invention relates to a specific adsorbing material for removing hepatitis B virus protein in blood plasma, and a preparation method of the adsorbing material, and discloses a high polymer material which is prepared by coupling sepharose gel with gene-modified sodion taurocholic acid cotransporting polypeptide. The preparation method of the material comprises the steps of reacting the sepharose gel, which is taken as a carrier matrix, with a bi-glycidyl ether coupling reagent to obtain an active carrier, and subsequently, conducting coupling reaction on the active carrier with the sodion taurocholic acid cotransporting polypeptide which is fused with polypeptide tags. The synthesis method of the material is simple and convenient, the process route is short and the preparation is safe; and the material has the characteristics of strong specificity, high adsorption rate to the hepatitis B virus protein, good regenerability, harmlessness and no heat source reaction, and can be applied to clinical adsorption treatment to eliminate the hepatitis B virus protein in blood plasma in a specificity mode.

The present invention relates to preparation of target liposom and uses thereof, particularly to the target hepatocellular compound of formula 1, the composition and pharmaceutical composition containing the compound for delivering drugs. In formula 1, X is a polypeptide derived from hepatitis B virus adventitial protein PreS1 zone, specifically binding with natrium ion-taurocholic acid co-transferred polypeptide (NTCP); B is a maleimide-polyethyleneglycol-stearoyl phosphatidyl ethanolamine polymer represented by formula 2; in formula 2, n is an integer of 2-100, DSPE is stearoyl phosphatidyl ethanolamine; X is linked with B by the maleimide portion of formula 2.

The invention relates to synthesis of a novel sodium taurocholate cotransporting polypeptide (NTCP) inhibitor and inhibiting effects of the inhibitor on the NTCP. The experimental research indicates that the compound has high inhibition activity for NTCP and indicates directions for antivirus, anti-bile siltation and metabolic regulation effects of anti-bile acid transporting drugs. The compound or composition thereof is hopeful to be developed into a novel NTCP inhibitor with great potential.

The invention provides a composition comprising an inhibitor of Na+-taurocholate cotransporting polypeptide (NTCP) and a active ingredient selected from the group consisting of a nucleoside analogue such as lamivudine, telbivudine, or entecavir, a nucleotide analogue such as tenofovir, adefovir and an immunomodulator such as interferon alpha. The NTCP inhibitor inhibits HBV / HDV entry into a cell and is preferably derived from an HBV pre-S1 peptide. Also provided are methods of treating HBV and HDV infection, hepatitis B and D, or chronic hepatitis B and D.

An inhibitor of Na+-taurocholate cotransporting polypeptide (NTCP) for use in a method of treatment of primary biliary cirrhosis, atherosclerosis, or an NRLP3 inflammasome-associated disease in a subject.

The invention discloses a compound oral solution containing pholcodine, prepared from, by weight, 4-6 arts of pholcodine, 6-8 parts of triprolidine, 2-4 parts of glutathione, 15-20 parts of radix isatidis, 5-12 parts of stevioside, 8-12 parts of artemisia apiacea, 4-10 parts of fresh ginger, 4-8 parts of andrographis paniculata, 4-8 parts of semen ziziphi spinosae, 2-6 parts of liquorice root, 1-2 parts of taurocholic acid, 2-4 parts of honey, 0.2-0.4 parts of Pu-erh tea extract, 0.2-0.4 parts of celery leaf extract, and 0.2-0.4 parts of blueberry extract; Compared with the prior technology, the compound oral solution has synergistic effect between the raw material components, the treatment effect is well with quick effect, the drug resistance is small, the medicinal safety is high, the side effect is small, the stability is good, the shelf life is long , which is easy to carry, the preparing process is simple, suitable for large-scale production and so on.

The invention discloses a production process of Niuchan granules with good palatability. According to the present invention, at the clear paste preparation stage during Niuchan granule production, a clear paste and a beta-cyclodextrin saturated aqueous solution are uniformly mixed and stirred, cold preservation, filtration and drying are performed to obtain a beta-cyclodextrin inclusion compound,the beta-cyclodextrin inclusion compound, betaine, fishy attractant and sodium glutamate are uniformly mixed according to a mass ratio of 97:1.5:1:0.5, and a required auxiliary is added to prepare theNiuchan granules; by using the molecular coating technology, taurocholic acid affecting the palatability, venenum bufonis and borneol are coated with beta-cyclodextrin while the flavoring agent is added, such that the poor taste of the Niuchan granules is significantly reduced; with the application of the molecular coating technology to prepare the Niuchan granules, the stability of the drug is increased, and the adverse effects of the oxidation effect, the temperature, the pH value and other factors on the effective components are avoided; and the production process is suitable for the veterinary dosage forms of known Niuchan granules with different treatment purposes and different use methods.

The invention discloses a synthetic method of taurocholic acid. The method comprises the following steps: A, mixing and stirring cholic acid with acetone and cooling to -10 to 30 DEG C, adding organic alkali, dripping ethyl chloroformate below 30 DEG C after evenly stirring, reacting for 1-3 hours after dripping is finished, and filtering to obtain filtrate; B, adding the filtrate in the step A to a solution formed by taurine and water, adjusting the pH to 7-11 by using organic alkali, then reacting at 20-30 DEG C for 3-5 hours, and filtering to obtain filtrate after reaction is finished; C, adjusting the pH of the filtrate in the step B to below 1 by using 10-30% of hydrochloric acid, concentrating in vacuum at 40-65 DEG C to dry, adding methanol, heating for dissolving, adding acetone to evenly stir, and cooling to -5 to 0 DEG C for crystallizing; filtering after crystallization is finished; washing a filter cake by acetone, draining and drying in vacuum. The invention aims at providing the synthetic method of taurocholic acid, which is simple in technology, relatively low in production cost, high in yield of taurocholic acid, and convenient for industrial production.

The invention relates to an immunomodulator for treating lung metastasis of colorectal cancer and a composition for prediction and detection of the immunomodulator, the immunomodulator comprises a substance for inhibiting deletion of a Bmal1 gene and / or a substance for inhibiting deletion of a Per1 gene and a Per2 gene, and the composition for predicting or detecting lung metastasis of colorectal cancer comprises a reagent for detecting Helicobacter helicobacter and Lacnoctustridium bacteroides, a reagent for detecting Helicobacter helicobacter and Lacnoctustridium bacteroides, and a reagent for predicting or detecting lung metastasis of colorectal cancer. And / or a reagent for detecting bile acid taurocholic acid. The development process of colorectal cancer lung metastasis is influenced by adjusting the tumor immune microenvironment, the risk of colorectal cancer lung metastasis is predicted by detecting the abundance of intestinal bacteria and metabolites thereof, the detection mode is simple and convenient, and accurate detection is convenient to achieve.

The invention relates to synthesis of a novel sodium taurocholate cotransporting polypeptide (NTCP) inhibitor and inhibiting effects of the inhibitor on the NTCP. The experimental research indicates that the compound has high inhibition activity for NTCP and indicates directions for antivirus, anti-bile siltation and metabolic regulation effects of anti-bile acid transporting drugs. The compound or composition thereof is hopeful to be developed into a novel NTCP inhibitor with great potential.

An inhibitor of Na+-taurocholate cotransporting polypeptide (NTCP) for use in a method of treatment of primary biliary cirrhosis, atherosclerosis, or an NRLP3 inflammasome-associated disease in a subject.